Theravance Biopharma (TBPH) Cash & Equivalents Growth (1y) (2015 - 2026)
Theravance Biopharma (TBPH) Cash & Equivalents Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 160.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.46% |
| Dec 31, 2025 | 343.97% |
| Sep 30, 2025 | 647.60% |
| Jun 30, 2025 | 508.32% |
| Mar 31, 2025 | 105.47% |
| Dec 31, 2024 | -4.42% |
| Sep 30, 2024 | -67.39% |
| Jun 30, 2024 | -56.11% |
| Mar 31, 2024 | -71.31% |
| Dec 31, 2023 | -86.74% |
| Sep 30, 2023 | -82.87% |
| Jun 30, 2023 | 20.97% |
| Mar 31, 2023 | 98.87% |
| Dec 31, 2022 | 231.45% |
| Sep 30, 2022 | 244.69% |
| Jun 30, 2022 | -57.41% |
| Mar 31, 2022 | -17.23% |
| Dec 31, 2021 | 10.42% |
| Sep 30, 2021 | 30.17% |
| Jun 30, 2021 | 95.68% |